Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.
Seema A. Bhat, MD, hematologist, The Ohio State University Comprehensive Cancer Center–James, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia (CLL).
With the introduction of targeted therapy, CLL continues to be a rapidly evolving field, says Bhat.
Targeted therapies are given indefinitely, which can add toxicity and financial burden and decrease compliance, Bhat explains.
However, combining targeted agents may induce better and deeper remissions, which could allow for time-limited options, says Bhat.
Time-limited combinations could reduce the long-term adverse effects and financial toxicity that are associated with indefinite treatment, concludes Bhat.